ClinVar Miner

Submissions for variant NM_007194.4(CHEK2):c.14C>T (p.Ser5Leu)

gnomAD frequency: 0.00007  dbSNP: rs201084748
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 10
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000129718 SCV000184521 uncertain significance Hereditary cancer-predisposing syndrome 2023-09-08 criteria provided, single submitter clinical testing The p.S5L variant (also known as c.14C>T), located in coding exon 1 of the CHEK2 gene, results from a C to T substitution at nucleotide position 14. The serine at codon 5 is replaced by leucine, an amino acid with dissimilar properties. This variant has been identified in multiple breast cancer and control cohorts across studies (Le Calvez-Kelm F et al. Breast Cancer Res., 2011 Jan;13:R6; Young EL et al. J. Med. Genet., 2016 06;53:366-76; Decker B et al. J. Med. Genet., 2017 11;54:732-741; Hauke J et al. Cancer Med, 2018 04;7:1349-1358). This alteration was also observed in one ovarian cancer patient in a cohort of 3251 individuals who met eligibility criteria for hereditary breast and ovarian cancer syndrome (Lerner-Ellis J et al. J Cancer Res Clin Oncol, 2021 Mar;147:871-879). In addition, this variant was identified in a cohort of 681 ancestrally diverse, healthy subjects (Bodian DL et al. PLoS One, 2014 Apr;9:e94554). This amino acid position is poorly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis and behaved as functional in an in vivo, yeast-based growth rate assay (Delimitsou A et al. Hum. Mutat., 2019 05;40:631-648). Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.
GeneDx RCV000656829 SCV000211004 uncertain significance not provided 2022-12-16 criteria provided, single submitter clinical testing Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant does not alter protein structure/function; Observed in individuals with breast, colorectal, and other cancers, as well as unaffected controls (Le Calvez-Kelm et al., 2011; Yurgelun et al., 2015; Decker et al., 2017; Yurgelun et al., 2017; Hauke et al., 2018); Published functional studies demonstrate cell growth comparable to wild-type in an in vivo yeast-based assay (Delimitsou et al., 2019); This variant is associated with the following publications: (PMID: 24728327, 26787654, 21244692, 28135145, 25980754, 28102005, 29522266, 28779002, 30851065, 35643632, 32885271, 36315097)
Invitae RCV000196102 SCV000254927 uncertain significance Familial cancer of breast 2024-02-01 criteria provided, single submitter clinical testing This sequence change replaces serine, which is neutral and polar, with leucine, which is neutral and non-polar, at codon 5 of the CHEK2 protein (p.Ser5Leu). This variant is present in population databases (rs201084748, gnomAD 0.02%). This missense change has been observed in individual(s) with CHEK2-related conditions (PMID: 21244692, 25980754, 28135145, 29522266). ClinVar contains an entry for this variant (Variation ID: 133886). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. Experimental studies have shown that this missense change does not substantially affect CHEK2 function (PMID: 30851065). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Counsyl RCV000196102 SCV000785867 uncertain significance Familial cancer of breast 2017-12-20 criteria provided, single submitter clinical testing
Color Diagnostics, LLC DBA Color Health RCV000129718 SCV000902865 likely benign Hereditary cancer-predisposing syndrome 2015-08-13 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000120550 SCV001737865 uncertain significance not specified 2021-05-29 criteria provided, single submitter clinical testing Variant summary: CHEK2 c.14C>T (p.Ser5Leu) results in a non-conservative amino acid change in the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 6.9e-05 in 245168 control chromosomes. This frequency is not significantly higher than expected for a pathogenic variant in CHEK2 causing Hereditary Breast And Ovarian Cancer Syndrome (6.9e-05 vs 0.00031), allowing no conclusion about variant significance. c.14C>T has been reported in the literature in individuals affected with breast cancer as well as unaffected controls and as a VUS in settings of multigene panel testing on individuals with colorectal cancer (example, Calvez-Kelm_2011, Yurgelun_2017). These report(s) do not provide unequivocal conclusions about association of the variant with Hereditary Breast And Ovarian Cancer Syndrome. At least one publication reports experimental evidence evaluating an impact on protein function. These results showed no damaging effect of this variant in a yeast functional experimental system evaluating the ability to repair MMS (methyl-methanesulfonate) induced DNA damage (Delimitsou_2019). Five clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation (likely benign, n=1; VUS, n=4). Some submitters cite overlapping evidence utilized in the context of this evaluation. Based on the evidence outlined above, the variant was classified as uncertain significance.
Quest Diagnostics Nichols Institute San Juan Capistrano RCV000656829 SCV002046597 likely benign not provided 2023-07-31 criteria provided, single submitter clinical testing A yeast-based study indicates the variant had neutral effects on CHEK2 protein function (PMID: 30851065 (2019)). Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is benign. Taking into account the available information, we are unable to determine the clinical significance of this variant.
Myriad Genetics, Inc. RCV000196102 SCV004020181 likely benign Familial cancer of breast 2023-03-09 criteria provided, single submitter clinical testing This variant is considered likely benign. This variant is strongly associated with less severe personal and family histories of cancer, typical for individuals without pathogenic variants in this gene [PMID: 25085752].
ITMI RCV000120550 SCV000084704 not provided not specified 2013-09-19 no assertion provided reference population
Department of Pathology and Laboratory Medicine, Sinai Health System RCV001355777 SCV001550755 uncertain significance Malignant tumor of breast no assertion criteria provided clinical testing The CHEK2 p.Ser5Leu variant was identified in 2 of 2606 proband chromosomes (frequency: 0.001) from individuals or families with breast cancer and was present in 1 of 2218 control chromosomes (frequency: 0.001) from healthy individuals (Le Calvez-Kelm 2011). The variant was also identified in the following databases: dbSNP (ID: rs201084748) as With Uncertain significance allele, ClinVar (classified as uncertain significance by Ambry Genetics, GeneDx, Invitae), Clinvitae (classified as uncertain significance by ClinVar, Invitae). The variant was not identified in Cosmic, MutDB, Zhejiang Colon Cancer Database, databases. The variant was identified in control databases in 16 of 239848 chromosomes at a frequency of 0.0001 in the following populations: European in 12 of 106232 chromosomes (freq.0.0001), African in 3 of 14996 chromosomes (freq. 0.0002), Asian in 1 of 30688 chromosomes (freq. 0.00003) (Genome Aggregation Consortium Feb 27, 2017). The p.Ser5 residue is not conserved in mammals and four out of five computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) do not suggest a high likelihood of impact to the protein; however, this information is not predictive enough to rule out pathogenicity. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) do not predict a difference in splicing. In summary, based on the above information, the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.